EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

A Multicenter Prospective Cohort Study on the Use of Weight‐Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer‐Associated Venous Thromboembolism—The WAVe Study

Tzu-Fei Wang iD, Erik Yeo, Peter L Gross, Chantal Séguin, Cynthia Wu, Sudeep Shivakumar, Ranjeeta Mallick, Aurélien Delluc iD, Julien D'Astous, Miriam Kimpton, Guillaume Roberge iD, Deborah M Siegal und 3 weitere

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70127 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Tzu-Fei Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa at the Ottawa Hospital, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Dalteparin, Venous Thromboembolism, Neoplasms, Anticoagulants. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with cancer‐associated thrombosis (CAT) are commonly treated with low‐molecular‐weight heparin (LMWH), but whether dose capping is needed in patients over 90 kg is unclear. We conducted the WAVe study, a multicenter prospective cohort study in adult patients (≥ 18 years) with acute CAT and a weight of over 90 kg starting anticoagulation. Patients received weight‐adjusted dalteparin at 200 IU/kg per day (up to 33 000 IU) for 30 (± 4) days, after which anticoagulation was continued per clinician discretion and followed for 6 months. The primary outcome was major bleeding (MB) at 30 days. Secondary outcomes included objectively confirmed recurrent venous thromboembolism (VTE) at 30 days and trough anti‐Xa levels. The cumulative incidences of outcomes were estimated by time‐to‐event analysis, with death as a competing risk. The study stopped early due to recruitment challenges after 91 patients. Median weight and daily dose of dalteparin were 107.5 kg and 22 500 IU, respectively. Three patients had a MB episode for a cumulative incidence of 5.3% (95% CI 1.1%–14.8%) at 30 days. One patient had recurrent VTE for a cumulative incidence of 1.2% (95% CI 0.1%–5.7%) at 30 days. No significant bioaccumulation noted up to Day 30 based on trough anti‐Xa levels. The median Day 7 trough anti‐Xa levels were higher in those with bleeding events within 30 days compared to those without (0.6 vs. 0.2 IU/mL, p = 0.01). Our results suggest that weight‐adjusted dosing of dalteparin in patients over 90 kg is associated with acceptable rates of bleeding and thrombosis. Trial Registration: NCT03297359

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DalteparinVenous ThromboembolismNeoplasmsAnticoagulantsHumansMaleMiddle AgedFemaleProspective StudiesAgedHemorrhageAdultBody WeightAcute DiseaseAged, 80 and over

Stichwörter der Autor:innen

anticoagulationcancerlow‐molecular‐weight heparinobesitythromboembolismweight adjusted

Substanzen

DalteparinAnticoagulants

Autor:innen und Institutionen

  • Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa at the Ottawa Hospital, Ottawa, Ontario, Canada.
  • Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Department of Medicine, Division of Hematology, McGill University, Québec, Canada.
  • Department of Medicine, Division of Hematology, University of Alberta, Edmonton, Alberta, Canada.
  • Department of Medicine, Nova Scotia Health, Dalhousie University, Halifax, Nova Scotia, Canada.

ORCID-Profile: Tzu-Fei Wang, Aurélien Delluc, Guillaume Roberge, Tobias Tritschler

Förderung

  • Pfizer

Zitieren

APA

Wang, T. F., Yeo, E., Gross, P. L., Séguin, C., Wu, C., Shivakumar, S., Mallick, R., Delluc, A., D'Astous, J., Kimpton, M., Roberge, G., Siegal, D. M., Tritschler, T., Le Gal, G., & Carrier, M. (2026). A Multicenter Prospective Cohort Study on the Use of Weight‐Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer‐Associated Venous Thromboembolism—The WAVe Study. American Journal of Hematology. https://doi.org/10.1002/ajh.70127

Vancouver

Wang TF, Yeo E, Gross PL, Séguin C, Wu C, Shivakumar S, et al. A Multicenter Prospective Cohort Study on the Use of Weight‐Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer‐Associated Venous Thromboembolism—The WAVe Study. American Journal of Hematology. 2026. doi:10.1002/ajh.70127

BibTeX
@article{Wang2026,
  author = {Wang, Tzu-Fei and Yeo, Erik and Gross, Peter L and Séguin, Chantal and Wu, Cynthia and Shivakumar, Sudeep and Mallick, Ranjeeta and Delluc, Aurélien and D'Astous, Julien and Kimpton, Miriam and Roberge, Guillaume and Siegal, Deborah M and Tritschler, Tobias and Le Gal, Grégoire and Carrier, Marc},
  title = {A Multicenter Prospective Cohort Study on the Use of Weight‐Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer‐Associated Venous Thromboembolism—The WAVe Study},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70127}
}
Kostenlos starten →